Aesica recruits new Business Development Manager to aid sales drive across German, Austrian and Swiss Markets
Aesica has appointed Nadine K. Reuter to the position of Business Development Manager, Finished Dose with responsibility for assisting in the drive to expand revenues from contract manufacturing activities across Germany, Austria and Switzerland. The new role encompasses growing new business, both by working closely with existing customers and through the development of new customer relationships, in addition to raising the profile of Aesica across the region.
Based in Germany, Nadine’s primary focus consists of marketing formulation development, finished dose commercial manufacturing and packaging services to current and new customers in the countries concerned.
Prior to joining Aesica, Nadine K. Reuter worked in Germany as Head of Sales and Business Development, Life Sciences, at Esau & Hueber GmbH, a member of the Bauer Group. Prior to this, she served as Sales Manager at NNE Pharmaplan, targeting pharmaceutical and biotechnology companies in the German and Austrian regions. Earlier, she worked as a Sales Engineer in the biopharmaceuticals division of Pall Corporation focused on the Bayern and Baden Württemberg areas.
Commenting on Nadine K. Reuter’s appointment, Ian Muir, Managing Director, Finished Dose at Aesica commented: “We are delighted that Nadine has joined our European sales team and she will play an important role in driving sales and business growth in the region. We already enjoy significant business and client servicing, carried out from our German sites, located in Zwickau and Monheim, and look forward to utilising Nadine’s sales expertise and knowledge in formulation development, finished dose manufacture and packaging, to help drive new business from existing and new customers located in the countries concerned.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance